drugset / Trial / NCT06011200

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population

NCT06011200

Phase 3 Completed 1000 enrolled CanSino Biologics Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The scientific name of meningococcus is Neisseria meningitidis (Nm), the causative agent of epidemic meningococcal meningitis (rheumatoid encephalitis), which colonizes the mucous membranes of the human nasopharynx or causes local infection and can cross the mucosal barrier to cause invasive bacteremia or epidemic meningococcal meningitis, meningococcus can often cause serious disease epidemics worldwide, the main clinical features of its infection are fever, rash and meningitis, the most common clinical manifestation is acute bacterial meningitis.

Timeline

Start
2023-09-16
Primary completion
2023-12-11
Completion
2024-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject MCV4 Vaccine 0.5 ml Intramuscular
Comparator MSPV4 Vaccine 0.5 ml Subcutaneous